

Notice of Allowability	Application No.	Applicant(s)	
	10/697,926	LOHRAY ET AL.	
	Examiner	Art Unit	
	Sabiha Qazi	1616	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 23 July 2004.
2. ☒ The allowed claim(s) is/are 1-3.
3. ☒ The drawings filed on 23 July 2004 are accepted by the Examiner.
4. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☒ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☒ Certified copies of the priority documents have been received in Application No. 08/777,627.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|--|
| 1. <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 6. <input type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date _____. |
| 3. <input checked="" type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____ | 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9. <input type="checkbox"/> Other _____. |

Art Unit: 1616

This application is re-issue of US 6,310,069. Presently claimed invention is drawn to intermediates of formula III. Claims 1 and 2 were allowed after the amendments in US Patent 6,310,069. Claim 3 is added now to include preparation of some compounds covered by formula III (see remarks and amendments filed after allowance, paper no. 11/C, dated 7/21/01).

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

Claim 3 has been amended to be underlined:

"A compound selected from the group consisting of:

4-[2-[4-oxo-3,4-dihydro-3-quinazolinyl]ethoxy]benzaldehyde,

4-[2-[2-Methyl-4-oxo-3,4,-dihydro-3-quinazolinyl]ethoxy]benzaldehyde,

4-[2-[2-Ethyl-4-oxo-3,4-dihydro-3-quinazolinyl]ethoxy]benzaldehyde,

4-[2-[8-Aza-2-methyl-4-oxo-3,4-dihydro-3-quinazolinyl]ethoxy]benzaldehyde,

4-[[3-Methyl-4-oxo-3,4,-dihydro-2-quinazolinyl]methoxy]benzaldehyde,

4-[[3-Ethyl-4-oxo-3,4,-dihydro-2-quinazolinyl]methoxy]benzaldehyde,

4-[[1-methyl-4-oxo-1,4,-dihydro-2-quinazolinyl]methoxy]benzaldehyde,

3-Methoxy-4-[[3-Methyl-4-oxo-3,4,-dihydro-2-quinazolinyl]methoxy]benzaldehyde,

4-[2-[2-Ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl]ethoxy]benzaldehyde oxime,

Art Unit: 1616

N-[4-[2-[2-Ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl]ethoxy]benzyl]N-hydroxyurea,

4-[2-[2-Ethyl-4-methyl-6-oxo-1,6,-dihydro-1-pyrimidinyl]ethoxy]aniline,

4-[2-[2-Ethyl-4-oxo-3,4,-dihydro-3-quinazolinyl]ethoxy]aniline,

Ethyl 2-bromo-3-[4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl]ethoxy]phenyl]propanoate,

Ethyl 2-bromo-3-[4-[2-[2-ethyl-4-oxo-3,4-dihydro-3-quinazolinyl]ethoxy]phenyl]propionate,

3-[4-[2-[2-Ethyl-4-methyl-6-oxo-1,6,-dihydro-1-pyrimidinyl]ethoxy]phenyl]-2-hydroxypropanoic acid,

Ethyl 3-[4-[2-[2-Ethyl-4-methyl-6-oxo-1,6,-dihydro-1-pyrimidinyl]ethoxy]phenyl]-2-hydroxypropanoate,

4-[2-[2,5,6-Trimethyl-4-oxo-3,4-dihydro-thieno-[2.3-d]pyrimidin-3-yl]ethoxy]benzaldehyde,

4-[2-[2-Methyl-4-oxo-3,4-dihydro-3-quinazolinyl]ethoxy]aniline, and

Ethyl 2-bromo-3-[4-[2-[2-methyl-4-oxo-3,4-dihydro-3-quinazolinyl]ethoxy]phenyl]propanoate.”

REASONS FOR ALLOWANCE

1. The following is an examiner's statement of reasons for allowance:
2. Claims 1-3 are allowed. The closest prior art is Shukla et al. (DN 93:168217, CAPLUS, abstract of J. Indian Chem. Soc. (1979), 56 (12), 1237-8. Instant claims differ from the reference

Art Unit: 1616

in claiming different substituents at phenyl ring attached to Oxygen atom. In prior art R represents this substituent and in instant claims it is G.

3. Prior art does not teach nor suggest the specific substituents represented by G on phenyl ring as presently claimed.


Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sabiha Qazi whose telephone number is (571) 272-0622. The examiner can normally be reached on any business day.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on (571) 272-0887. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Thursday, December 9, 2004


SABIHA QAZI, PH.D
PRIMARY EXAMINER